Contemporaneous Risk Factors for Visual Acuity in Non-Infectious Uveitis

ABSTRACT

Introduction

We evaluated the associations of clinical and demographic characteristics with visual acuity (VA) with over 5 years in a subspecialty noninfectious uveitis population.

Methods

Retrospective data from 5,530 noninfectious uveitis patients were abstracted by expert reviewers, and contemporaneous associations of VA with demographic and clinical factors were modeled.

Results

Patients were a median of 41 years old, 65% female, and 73% white. Eyes diagnosed ≥5 years prior to cohort entry had worse VA (−1.2 lines) than those diagnosed <6 months prior, and eyes with cataract surgery performed prior to entry had worse VA (−5.9 lines) than those performed during follow-up. Vitreous haze (−4.2 lines for 3+ vs quiet), hypotony (−2.5 lines for ≤5 mm Hg vs 6–23 mm Hg), and CNV (−1.8 lines) all were strongly associated with reduced VA.

Conclusion

Factors associated with reduced VA included well-known structural complications, and lack of subspecialty care during cataract surgery.

KEYWORDS:

• Visual Acuity
• uveitis
• risk Factors

Declaration Of Interest Statement

Maxwell Pistilli, Sapna S. Gangaputra, Siddharth S. Pujari, Douglas A. Jabs, Grace A. Levy-Clarke, Hosne Begum, Tonetta D. Fitzgerald, and Nirali P. Bhatt, report no conflicts of interest. James T. Rosenbaum serves or has served as a consultant for Abbott Laboratories, Amgen, Allergan, Genentech, Novartis, and UCB and has been involved in clinical trials for Abbott Laboratories, Genentech, Lux Biosciences, and Eyegate Pharma. Jennifer E. Thorne serves a consultant for Allergan and XOMA. C. Stephen Foster serves as a lecturer for Alcon, Inspire, Ista, and Centocor; as a Consultant for Sirion; as a consultant and lecturer for Allergan and Bausch & Lomb; and as an equity owner for EyeGate. John H. Kempen serves as a consultant (DSMC Chair) for Gilead.

Additional information

Funding

This study was supported primarily by National Eye Institute Grant EY014943 (JHK). Additional support was provided by Research to Prevent Blindness, the Paul and Evanina Mackall Foundation, the Lois Pope Life Foundation (all of New York, NY), and Sight for Souls (Fort Myers, FL). JHK was an RPB James S Adams Special Scholar Award recipient, JET was an RPB Harrington Special Scholar Award recipient, and DAJ and JTR were Research to Prevent Blindness Senior Scientific Investigator Award recipients during the course of the study. GAL-C and RBN previously was supported by and HNS continues to be supported by intramural funds of the National Eye Institute. EBS receives support from the Department of Veterans’ Affairs. The funding sources had no role in the design, and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication;National Eye Institute [EY014943]; Lois Pope Life Foundation;Sight for Souls; Paul MacKall and Evanina Bell MacKall Trust.